XML 44 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2019
Nov. 30, 2017
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Jan. 31, 2016
May 13, 2010
Shareholders' Equity (Textual) [Abstract]                    
Repurchase outstanding common shares                 $ 10,000,000 $ 10,000,000
Repurchase of shares, value     $ (531,746) $ (703,790) $ (784,505) $ (1,195,225)        
Shelf Registration, sale of corporate securities (up to)   $ 100,000,000                
Proceeds from sales of common stock, net of offering costs             $ 0 $ 200,909    
Contribution of cash $ 300,000                  
Conversion of intercompany loans payable 700,000                  
WinHealth                    
Shareholders' Equity (Textual) [Abstract]                    
Investment through purchase of shares of CET Stock 1,000,000                  
Gloria Pharmaceuticals                    
Shareholders' Equity (Textual) [Abstract]                    
Cash payments for return of shares $ 800,000                  
Restricted Stock                    
Shareholders' Equity (Textual) [Abstract]                    
Restricted stock granted in period, shares             222,469 233,330    
Director                    
Shareholders' Equity (Textual) [Abstract]                    
Number of shares sold (in shares)     47,969              
Director | Restricted Stock                    
Shareholders' Equity (Textual) [Abstract]                    
Restricted stock awards, vesting period             1 year      
Common stock                    
Shareholders' Equity (Textual) [Abstract]                    
Repurchase of shares (in shares)     84,447 121,466 127,291 172,079 205,913 299,370    
Repurchase of shares, value     $ (531,746) $ (703,790) $ (784,505) $ (1,195,225) $ (1,200,000) $ (2,000,000.0)    
Common stock issued               30,704    
Proceeds from the sale of common stock, net of offering costs (in shares)         0 30,704